相关实验视频

Updated: Jun 30, 2025

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

科雷奥普西斯丁科里亚改善肥胖高血糖小鼠的能量代谢

Bingxin Huangfu¹, Minglan Yang^1,2, Jia Xu¹

¹Key Laboratory of Precision Nutrition and Food Quality, Ministry of Education, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, 100083, China.

|March 18, 2024

概括

红 (CT) 提取物显著改善了肥胖小鼠的葡萄糖不耐受性和胰岛素耐药性. 在CT中的主要活性化合物甲费醇通过调节关键代谢途径,显示出抗高血糖作用.

科学领域:

代谢研究的研究.
药理学药理学是指药理学的学科.
营养学科学营养学科学

背景情况:

肥胖引起的高血糖是越来越严重的健康问题.
众所周知,Coreopsis tinctoria (CT) 有助于改善能量代谢.
需要阐明CT在缓解高血糖症,特别是在肝脏中的具体机制.

研究的目的:

研究CT改善能量代谢和对抗高血糖的机制.
为了确定CT中负责这些效应的活性化合物.
探索CT在肝脏组织中准的分子通路.

主要方法:

将CT提取物 (水和乙醇) 给高脂肪饮食引起的肥胖小鼠.
使用网络药理学,液体染色学-质谱学 (LC-MS) 和肝脏转录组学.
培养L02细胞以评估抗高血糖效应.

主要成果:

CT水提取物显著缓解了葡萄糖不耐受和胰岛素抵抗.
凯姆菲洛被确定为具有显著抗高血糖作用的主要活性化合物.
在碳代谢,糖解/葡萄糖生成和MAPK通路中,凯姆费洛尔调节基因.

结论:

口服CT有效降低血糖,提高肥胖引起的高血糖症中的胰岛素敏感性.
凯姆费醇是中介CT的抗高血糖作用的关键功能成分.
CT的机制涉及肝脏中关键代谢和信号通路的调节.

关键词:

这种植物是Coreopsis tinctoria.过高血糖症的发生.凯姆菲罗尔醇是什么意思肝脏肝脏肝脏肝脏肥胖问题肥胖问题

更多相关视频

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

Published on: May 24, 2018

相关概念视频

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...